Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Agios Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06286046CT.gov A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mitapivat (this asset) | Agios Pharmaceuticals, Inc. | P2 | CCC · 53 |
| Folic Acid | Fuling Central Hospital of Chongqing City | P2/3 | BB |
| Spironolactone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | BB |
| Valsartan | Columbia University | P4 | BB |
| Lisinopril | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Nifedipine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Simvastatin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Finerenone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | B |
| Enalapril Maleate | Fuling Central Hospital of Chongqing City | P2/3 | B |
+9 more in the Diabetic Kidney Disease cohort
Other indications for Mitapivat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P3 | BB · 65 |
| Alpha Thalassemia Spectrum | — | P3 | B · 60 |
| Beta-Thalassemia Major | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Folic AcidFuling Central Hospital of Chongqing CityBB
- SpironolactoneHospital de Messejana Dr. Carlos Alberto Studart GomesBB
- ValsartanColumbia UniversityBB
- LisinoprilNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
- NifedipineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
Citation
Floatz Terminal. Mitapivat in Diabetic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mitapivat-diabetic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →